pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,917 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1888Endpoints1464Fierce Biotech779BioSpace767BioPharma Dive554raps254onclive165fda recalls122
therapy area
allOncology13092Rare Disease3386Immunology3069Cardiology2865Hematology2334Pulmonology2297Vaccines
  • Teva R&D chief Eric Hughes resigns as company pushes innovative medicines expansion
    Teva Pharmaceutical announced that its head of research and development, Eric Hughes, M.D., Ph.D., will resign, with his departure set to occur over the next few months. Hughes joined Teva in 2022…
    Fierce Biotech · 1d agoNeutral↗ source
  • Drugmakers urged to assess device capabilities and engage regulators early for combo products
    At the AFDO/RAPS Combination Products Summit, a panel of experts advised drugmakers that developing standalone medical devices to be used with their drugs requires careful evaluation of the devices…
    raps · 1d agoRegulatoryNeutral↗ source
← prev
page 2 of 77
next →
fda medwatch117
globenewswire health73
fda press62
1882
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
  • FDA puts drug repurposing front-and-center, says BioSpace podcast
    In a recent episode of BioSpace’s podcast “Denatured,” host Jennifer C. Smith-Parker spoke with Daniel Tillett, chief executive of Racura Oncology, and Sten Sörensen, chief executive of Cereno Scie…
    BioSpace · 1d agoRegulatoryNeutral↗ source
  • Early Alert: B. Braun Medical Inc. Updates Use Instructions for Caresite Micro Luer Access Device
    BBMI corrects Caresite devices due to issue with internal piston remaining depressed following disconnection, preventing the valve from fully closing.
    fda medwatch · 1d agoRegulatoryNeutral↗ source
  • UK MHRA launches AdvanceGxP to help drugmakers address good practice early
    The Medicines and Healthcare products Regulatory Agency in the United Kingdom has introduced a new service called AdvanceGxP. The initiative is designed to give pharmaceutical companies early guida…
    raps · 1d agoRegulatoryNeutral↗ source
  • FDA issues final guidance on 510(k) ownership transfers, shortening sections and adding Q&A
    The U.S. Food and Drug Administration has released a final guidance that spells out the duties of owners of 510(k) clearances when a product is sold or transferred to another company. The new docu…
    raps · 1d agoRegulatoryNeutral↗ source
  • Three series-C funded biotechs expand hiring, including Triveni Bio’s $65 M raise
    Three biotechnology companies that announced series C financing this year are actively hiring, signaling plans to scale operations. One of the firms secured a $140 million round and maintains offic…
    BioSpace · 1d agoDealNeutral↗ source
  • Survey finds most users find home diagnostic tests very helpful, but only a third view them as very accurate
    Det Norske Veritas (DNV) surveyed 12,500 people in 17 countries to gauge attitudes toward home diagnostic tests and other medical devices used at home. Among respondents who had used home diagnost…
    Fierce Biotech · 1d agoNeutral↗ source
  • Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic disease
    Sanofi’s Infilbray is designed to cross the blood-brain barrier, allowing the drug to prevent the toxic buildup of disease-causing lipids in the brain for patients with type 3 Gaucher disease.
    BioSpace · 1d ago↗ source
  • GSK receives FDA accelerated approval for neladalkib (Nelkarmi) in ALK-positive lung cancer, second win from Nuvalent deal
    GSK announced that the FDA has granted accelerated approval to its tyrosine kinase inhibitor neladalkib, to be sold under the brand name Nelkarmi, for patients with ALK‑positive non‑small cell lung…
    BioSpace · 2d agoApprovalPositive↗ source
  • Pfizer signs $2.6 billion deal with China's Starna to acquire in vivo CAR-T programs for autoimmune diseases
    Pfizer announced a $2.6 billion agreement with Chinese biotech Starna Therapeutics to obtain rights to three preclinical in vivo CAR-T candidates aimed at autoimmune diseases. The deal includes a…
    Fierce Biotech · 2d agoDealPositive↗ source
  • Pfizer partners with China's Starna Therapeutics on up to $2.6B in vivo CAR-T deal for autoimmune diseases
    Pfizer announced a collaboration with Chinese biotech Starna Therapeutics to develop in vivo CAR-T therapies targeting autoimmune diseases. The agreement covers three preclinical CAR-T programs, w…
    BioSpace · 2d agoDealPositive↗ source
  • BMS reports early Alzheimer’s psychosis data for Cobenfy showing reduced hallucinations but safety concerns remain
    At the Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston, Bristol Myers Squibb presented early Phase 3 ADEPT data for KarXT, marketed as Cobenfy, in patients with Alzheimer’s disea…
    BioSpace · 2d agoPositive readoutNeutral↗ source
  • Government policies strain funding and operations for small biotech firms
    Cassel Salpeter's latest healthcare investment report says that recent government actions, including FDA staff reductions, slower federal research grants and higher tariffs, are creating a tough fu…
    BioSpace · 2d agoRegulatoryNegative↗ source
  • AbbVie inks up to $2.5 billion deal with Disco to pursue bispecific cancer therapeutics
    AbbVie announced a collaboration with German biotech Disco Pharmaceuticals that could be worth up to $2.5 billion. The agreement provides a $40 million upfront payment, with the balance linked to…
    Fierce Biotech · 2d agoDealPositive↗ source
  • FDA rejects Summit Therapeutics' PD-1/VEGF bispecific ivonescimab after Phase 3 failure
    The U.S. Food and Drug Administration declined to grant approval for ivonescimab, a bispecific antibody that targets PD‑1 and VEGF and was being developed by Summit Therapeutics in collaboration wi…
    BioSpace · 2d agoRegulatoryNegative↗ source
  • Biogen's tau antisense therapy shows 38% slower decline in 2-year Alzheimer extension study
    Biogen presented new data from the open‑label extension of its phase 2 Celia trial at the CTAD 2026 conference. The update focused on the tau‑targeting antisense oligonucleotide, diranersen, admini…
    Fierce Biotech · 2d agoPositive readoutPositive↗ source
  • Priavoid’s Alzheimer’s drug misses primary goal in phase 2 trial, shows later cognitive benefit signal
    German biotech Priavoid reported that its oral all-D-peptide candidate, PRI-002, did not achieve the primary efficacy endpoint in the phase 2 PRImus-AD study of patients with mild cognitive impairm…
    Fierce Biotech · 2d agoNegative readoutNegative↗ source
  • Cognito Therapeutics' Phase 3 HOPE Study Misses Primary Goal but Shows Promise in Mild Alzheimer’s Patients
    Cognito Therapeutics announced that its phase 3 HOPE trial of Spectris AD, a home-based device delivering light and sound stimulation, did not achieve its primary efficacy endpoint. The trial enro…
    Fierce Biotech · 2d agoNegative readoutNeutral↗ source
  • Merck halts development of BTK inhibitor nemtabrutinib after safety concerns
    Merck announced it is ending development of the oral BTK inhibitor nemtabrutinib (MK-1026), which it acquired in the $2.7 billion ArQule purchase. The decision follows a recommendation from an ext…
    BioSpace · 2d agoRegulatoryNegative↗ source
  • Pfizer CEO warns China will be major biotech competitor by 2030 and urges AI-driven cost cuts
    At the Jefferies Global Healthcare Conference in London, Pfizer chief Albert Bourla said China is rapidly building its biotech sector and could become the company's biggest rival by 2030, surpassin…
    BioSpace · 2d agoNeutral↗ source
  • FDA rejects Summit Therapeutics' ivonescimab, citing trial design and safety concerns
    Summit Therapeutics received a Complete Response Letter from the FDA rejecting its application for ivonescimab, a PD-1xVEGF combination intended for EGFR-mutated non-small cell lung cancer. The ag…
    BioSpace · 2d agoRegulatoryNegative↗ source
  • Acquisitions can tie big pharma to existing biotech partners, creating co-parenting challenges
    Acquiring a biotech that already works with another large pharmaceutical firm can bring extra obligations beyond the technology and pipeline being bought. The report highlights Merck KGaA’s planne…
    BioSpace · 2d agoDealNeutral↗ source
  • FDA clears Medtronic's MiniMed Fit tubeless insulin pump
    MiniMed, a Medtronic unit, announced that the FDA has granted clearance for its new tubeless insulin pump called MiniMed Fit. The device is designed to be worn for up to seven days and holds a 300…
    Fierce Biotech · 2d agoApprovalPositive↗ source
  • Merck halts $2.7 billion BTK inhibitor program after negative phase 3 data
    Merck announced it is discontinuing its BTK inhibitor nemtabrutinib program, ending three phase 3 trials in chronic lymphocytic leukemia and small lymphocytic lymphoma. The decision follows a reco…
    Fierce Biotech · 2d agoNegative readoutNegative↗ source